For decades, a silent compromise has shaped breast cancer research: the most common form of the disease — estrogen receptor-positive (ER+) breast cancer — has lacked a reliable animal model that mirrors its human biology. Mouse models, despite their dominance in oncology labs, consistently fail to replicate key hormonal and molecular features of ER+ tumors. That gap has real consequences for drug development and mechanistic understanding, and a new platform may finally begin to close it.
Published in PNAS, this work introduces somatic genome editing in rats as a viable method for constructing ER+ breast cancer models. Rather than relying on germline-modified mouse lines, the approach uses in vivo genome editing directly in rat mammary tissue to introduce oncogenic mutations, enabling tumor formation that more faithfully recapitulates the estrogen-driven biology characteristic of human ER+ breast cancer. The rat system appears to preserve hormonal signaling contexts that mouse physiology cannot replicate, making it particularly suited to modeling tumors where estrogen receptor activity is central to both disease progression and therapeutic response.
This is a meaningful methodological contribution rather than a paradigm shift in cancer biology itself. Rats have historically been underutilized in cancer modeling partly due to fewer genetic tools, so adapting somatic CRISPR-based editing to this species represents genuine technical progress. From a translational standpoint, better preclinical models could reduce the high attrition rate of ER+ breast cancer drugs that succeed in mice but fail in clinical trials — a persistent problem in the field. Key limitations remain: this is early-stage platform validation, and whether rat-derived tumor models will predict human drug responses better than current mouse systems requires prospective testing. Nonetheless, for the estimated 70% of breast cancer patients whose tumors are ER+, research built on more representative biology is a step worth tracking.